Passage Bio Restructures Remix Merger with Two-Step Tax-Free Structure and $70M Pre-Funded Warrant Financing
PASG sits 33% above its 52-week low of $3.29 on light trading volume (0.1× avg).
Summary
Passage Bio amended its reverse merger with Remix Therapeutics to a two-step tax-free structure and restructured the $70M Concurrent Financing to include pre-funded warrants, while preserving all original economic terms.
Key Events · M&A and Partnerships · PASG
-
Two-Step Merger Structure Adopted
The merger will now occur in two steps — Merger Sub merging into Remix, then the surviving entity merging into Merger Sub II — intended to qualify as a tax-free reorganization under Section 368(a).
-
Concurrent Financing Restructured with Pre-Funded Warrants
Investors may purchase pre-funded warrants to buy Remix common stock in lieu of shares, at $1.3861 per share and $1.3860 per warrant, for an aggregate subscription of approximately $70.0 million.
-
Remix Authorized Shares Increased
The Remix Charter Amendment increases authorized Remix common stock from 162,000,000 to 300,000,000 shares to accommodate the financing and merger.
-
Economic Terms Unchanged
The Amended and Restated Merger Agreement preserves the original economics: Remix equity value of $226 million, Passage equity value of $20 million, minimum Concurrent Financing proceeds of $99.9 million, and the December 24, 2026 outside date.
Analysis · PASG · Life Sciences
On September 2, 2026, Passage Bio and Remix Therapeutics amended their merger agreement, converting the deal from a single-step to a two-step merger intended to qualify as a tax-free reorganization under Section 368(a). The Concurrent Financing was also restructured: investors may now purchase pre-funded warrants instead of Remix common stock, at $1.3861 per share and $1.3860 per warrant, for an aggregate subscription of approximately $70 million. The Remix Charter Amendment increases authorized shares from 162 million to 300 million. These changes preserve the original economic terms — Remix equity value of $226 million, Passage equity value of $20 million, minimum Concurrent Financing proceeds of $99.9 million, and the December 24, 2026 outside date — while adding structural flexibility to satisfy tax and SEC requirements. The two-step structure and pre-funded warrant mechanics are new material terms that affect how the deal closes and how investors receive their consideration.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASG was trading at $4.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.